Summary China’s NMPA approved CARsgen’s satri-cel, the first CAR-T therapy approved anywhere in the world for a solid tumor. What Happened The approval covers Claudin18.2-positive advanced gastric and gastroesophageal junction cancer after at least two prior lines of therapy. Deep…
Summary Be Biopharma terminated the Phase 1/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B. What Happened The trial stopped after enrolling five patients. The company stated the decision was strategic and not…
Summary Intellia reported additional positive Phase 3 data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, reinforcing earlier primary endpoint success and strengthening the regulatory profile of one of the most advanced in vivo CRISPR programs globally. What Happened New Phase…
Summary Syndax presented interim real-world evidence from the ROAR study at EHA 2026 showing an 82% overall response rate and 64% CR/CRh rate among heavily pretreated patients with relapsed or refractory NPM1-mutated or KMT2A-rearranged acute leukemia treated with revumenib. The…
Summary Sobi presented new clinical and real-world evidence across four rare hematology franchises at EHA 2026: PNH (pegcetacoplan), ITP (avatrombopag), HLH (emapalumab), and myelofibrosis (pacritinib). While no pivotal efficacy readouts were disclosed, the package reinforces the commercial durability and clinical…
Summary Johnson & Johnson presented pivotal ENERGY Phase 2/3 data showing statistically significant durable hemoglobin responses for IMAAVY in warm autoimmune hemolytic anemia, supporting its February 2026 sBLA filing. What Happened Patients receiving IMAAVY achieved durable hemoglobin responses at roughly…
Summary Climb Bio presented the first clinical data for budoprutug, an anti-CD19 monoclonal antibody, in primary immune thrombocytopenia (ITP). Early Phase 1b results demonstrated robust B-cell depletion, encouraging safety, and meaningful platelet responses in heavily pretreated patients, introducing a new…
Summary AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a setting with significant unmet need…
Summary Karyopharm delivered one of the most important myelofibrosis datasets of 2026. In the Phase 3 SENTRY study, selinexor plus ruxolitinib nearly doubled spleen response rates versus ruxolitinib alone (49.8% vs 28.0%) and generated an early overall survival signal (HR…
Summary Kelonia Therapeutics presented updated ASCO 2026 data supporting continued advancement of its in vivo CAR-T platform, which engineers CAR-T cells directly inside patients using targeted lentiviral delivery technology. What Happened Kelonia shared updated clinical progress from its in vivo…
